

| | | | | | | | |
|--|--|--|--|---|--|--------------------------------------|--|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 October 14, 2008 | | | | Attorney Docket No. 056291-5303 | | Application No. 10/594,233 | |
| | | | | Applicants: Stephen WEDGE et al. | | | |
| | | | | Filing Date: September 25, 2006 | | Group Art Unit: 4161 | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--------------|----------------|------------------|---------------|-----------|-------------|--|
| Initial | Document No. | Date | Name | Class | Sub-Class | Filing Date | |
| | 1. | US 20030144298 | July 31, 2003 | Curwen et al. | | | |
| | 2. | US 20060142316 | June 29, 2006 | Wedge et al. | | | |
| | 3. | US 20060160775 | July 20, 2006 | Wedge | | | |
| | 4. | US 20060167024 | July 27, 2006 | Wedge | | | |
| | 5. | US 20070135462 | June 14, 2007 | Wedge | | | |
| | 6. | US 20080015205 | January 17, 2008 | Wedge | | | |
| | 7. | US 20080113039 | May 15, 2008 | Wedge | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----------------|------------------|-------|-----------|-------------|--|--|
| Document No. | Date | Country | Class | Sub-Class | Translation | | |
| 8. | WO 00/47212 | August 17, 2000 | WIPO | | | | |
| 9. | WO 01/74360 | October 11, 2001 | WIPO | | | | |
| 10. | WO 2004/071397 | August 26, 2004 | WIPO | | | | |
| 11. | WO 2005/004871 | January 20, 2005 | WIPO | | | | |
| 12. | WO 2005/004872 | January 20, 2005 | WIPO | | | | |
| 13. | WO 2005/061488 | July 7, 2005 | WIPO | | | | |
| 14. | WO 2005/092384 | October 6, 2005 | WIPO | | | | |
| 15. | WO 2005/092385 | October 6, 2005 | WIPO | | | | |
| 16. | WO 2006/035203 | April 6, 2006 | WIPO | | | | |
| 17. | WO 2007/003933 | January 11, 2007 | WIPO | | | | |
| 18. | WO 2007/071970 | June 28, 2007 | WIPO | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---|--|
| 19. | Ferrari et al. "Three drugs schedule in metastatic colorectal cancer (MCC). A phase II study of sequential irinotecan (CPT11), oxaliplatin (I-OHP) plus folinic acid (FA) and short fluorouracil (5FU) infusion" European Journal of Cancer. Supplement, 1(5): S76 (2003) | |
| 20. | Malik et al. "Targeting VEGF ligands and receptors in cancer" Targets, 2(2):48-57 (2003) | |
| 21. | Marme "The impact of anti-angiogenic agents on cancer therapy" Journal of Cancer Research and Clinical Oncology 129(11): 607-620 (2003) | |
| 22. | Wheeler et al. "Novel approaches in oncology at AstraZeneca" European Journal of Cancer. Supplement, 1(8):3-8 (2003) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| | |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.